Patents by Inventor Karin Staaf

Karin Staaf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7691892
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: April 6, 2010
    Assignee: AstraZeneca AB
    Inventors: Martin Johansson, Alexander Minidis, Karin Staaf, David Wensbo, Donald McLeod, Louise Edwards, Methvin Isaac, Anne O'Brien, Abdelmalik Slassi, Tao Xin, Tomislav Stefanac
  • Patent number: 7585881
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: September 8, 2009
    Assignee: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tau Xin, Jalaj Arora
  • Patent number: 7576077
    Abstract: The present invention is directed to compounds of formula I: wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: August 18, 2009
    Assignee: Astrazeneca AB
    Inventors: David Wensbo, Martin Johansson, Alexander Minidis, Karin Staaf, Annika Kers, Louise Edwards, Methvin Isaac, Tom Stefanac, Abdelmalik Slassi, Don McLeod, Tao Xin
  • Publication number: 20090105252
    Abstract: Compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: October 2, 2006
    Publication date: April 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Lars Andersson, Erwan Arzel, Stefan Berg, Jeremy Burrows, Sven Hellberg, Fernando Huerta, Torben Pedersen, Tobias Rein, Didier Rotticci, Karin Staaf, Dominika Turek
  • Publication number: 20080188503
    Abstract: The present invention relates to a compound of formula (I): as a free base or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical formulations containing said compound and to the use of said compound in therapy. The present invention further relates to a process for the preparation of the compound of formula (I).
    Type: Application
    Filed: June 27, 2007
    Publication date: August 7, 2008
    Applicant: AstraZenaca AB
    Inventors: Jeremy Burrows, Fernando Huerta, Tobias Rein, Didier Rotticci, Karin Staaf, Dominika Turek
  • Publication number: 20080188502
    Abstract: The present invention relates to a compound of formula (I): as a free base or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical formulations containing said compound and to the use of said compound in therapy. The present invention further relates to a process for the preparation of compound of formula (I) and to new intermediates used therein.
    Type: Application
    Filed: June 27, 2007
    Publication date: August 7, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeremy Burrows, Fernando Huerta, Fredrik Lake, Torben Pedersen, Didier Rotticci, Tobias Rein, Karin Staaf, Ulrika Yngve
  • Publication number: 20080045571
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: February 21, 2008
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20080015234
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: January 17, 2008
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20080015204
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: January 17, 2008
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20070293545
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: August 18, 2007
    Publication date: December 20, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20070197549
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds, and to the use of said compounds in therapy.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 23, 2007
    Applicant: AstraZeneca AB
    Inventors: Martin Johansson, Alexander Minidis, Karin Staaf, David Wensbo, Donald McLeod, Louise Edwards, Methvin Isaac, Anne O'Brien, Abdelmalik Slassi, Tao Xin, Tomislav Stefanac
  • Publication number: 20070185100
    Abstract: The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, X5, X6, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicant: AstraZeneca AB
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Annika Kers, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, David Wensbo, Tao Xin, Bjorn Holm
  • Publication number: 20070185178
    Abstract: The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, X7, X8, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy, especially for the treatment of mGluR5 receptor mediated disorders, and for the treatment of neurological disorders, psychiatric disorders, gastrointestinal disorders and pain disorders.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicants: AatraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Johan Malmberg, Alexander Minidis, Karin Staaf, Abdelmalik Slassi, David Wensbo, Tao Xin, Tomislav Stefanac
  • Publication number: 20070185095
    Abstract: The present invention is directed to compounds of formula: (I); wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds for treating gastrointestinal disorders.
    Type: Application
    Filed: February 17, 2005
    Publication date: August 9, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Martin Johansson, David Wensbo, Alexander Minidis, Karin Staaf, Annika Kers, Louise Edwards, Methvin Isaac, Tomislav Stefanac, Abdelmalik Slassi, Donald McLeod, Tao Xin
  • Publication number: 20070179188
    Abstract: The present invention relates to new compounds of formula (I), to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: February 15, 2005
    Publication date: August 2, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald Mcleod, Alexander Minidis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Publication number: 20060025414
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4 X5, X6, R1, R2, R3, m, n, and p are as defined as in formula I, or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: February 18, 2005
    Publication date: February 2, 2006
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Annika Kers, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, David Wensbo, Tao Xin, Bjorn Holm
  • Publication number: 20060019997
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4 X7, X8, R1, R2, R3, m, n, and p are as defined as in formula I, or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: February 18, 2005
    Publication date: January 26, 2006
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Johan Malmberg, Alexander Minidis, Karin Staaf, Abdelmalik Slassi, David Wensbo, Tomislav Stefanac, Tao Xin
  • Publication number: 20060009443
    Abstract: The present invention is directed to compounds of formula I: wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: February 18, 2005
    Publication date: January 12, 2006
    Inventors: David Wensbo, Martin Johansson, Alexander Minidis, Karin Staaf, Annika Kers, Louise Edwards, Methvin Isaac, Tom Stefanac, Abdelmalik Slassi, Don McLeod, Tao Xin
  • Publication number: 20060004021
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: February 18, 2005
    Publication date: January 5, 2006
    Inventors: Martin Johansson, Alexander Minidis, Karin Staaf, David Wensbo, Donald McLeod, Louise Edwards, Methvin Isaac, Anne O'Brien, Abdelmalik Slassi, Tao Xin, Tomislav Stefanac
  • Publication number: 20050272779
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: February 9, 2005
    Publication date: December 8, 2005
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora